StevenHseshengLinMDPhD

Radiation Oncology • Houston, TX

Thoracic Cancer

Professor

Join to view full profile

Dr. Lin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lin's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Fax+1 713-563-2366

Education & Training

Johns Hopkins UniversityResidency, Radiation Oncology, 2005 - 2009
Loma Linda University Health Education ConsortiumInternship, Internal Medicine, 2004 - 2005
University of California, Irvine, School of MedicineClass of 2004

Certifications & Licensure

FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2026
TN State Medical License 2023 - 2026
WA State Medical License 2023 - 2026
AL State Medical License 2023 - 2025
CA State Medical License 2006 - 2025
GA State Medical License 2023 - 2025
LA State Medical License 2023 - 2025
MS State Medical License 2023 - 2025
OK State Medical License 2020 - 2025
TX State Medical License 2009 - 2025
American Board of Radiology Radiation Oncology
Join now to see all

Clinical Trials

Trimodality Management of T1b Esophageal Cancers Start of enrollment: 2010 Oct 01
Completed
Phase 1, Phase 2
A Phase II Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Esophageal Cancer Start of enrollment: 2013 Feb 01
Completed
Phase 2
Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery Start of enrollment: 2013 Oct 28
Terminated
Phase 1
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer Start of enrollment: 2020 Nov 23
Recruiting
Phase 1
Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients Start of enrollment: 2021 Aug 24
Completed
Phase 1
Roles: Contact
REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE) Start of enrollment: 2023 Jan 10
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation Start of enrollment: 2024 Feb 05
Recruiting
Roles: Contact, Principal Investigator
18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer Start of enrollment: 2024 Nov 29
Not yet recruiting
Early Phase 1
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

1 citations
Personalized Composite Dosimetric Score-Based Machine Learning Model of Severe Radiation-Induced Lymphopenia Among Patients With Esophageal Cancer.
Yan Chu, Cong Zhu, Brian P Hobbs, Yiqing Chen, Peter S N van Rossum
International Journal of Radiation Oncology, Biology, Physics. 2024-11-15
Long-Term Clinical, Radiological, and Mortality Outcomes Following Pneumonitis in Nonsmall Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Retrospe...
Felipe Soto-Lanza, Lydia Glick, Colin Chan, Linda Zhong, Nathaniel Wilson
Clinical Lung Cancer. 2024-11-01
2 citations
Impact of cancer therapy on clonal hematopoiesis mutations and subsequent clinical outcomes.
Kevin T Nead, Taebeom Kim, LiJin Joo, Tina L McDowell, Justin W Wong
Blood Advances. 2024-10-08

Journal Articles

Recurrence Risk Based on Pathologic Stage After Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Implications for Risk-Based Postoperative Surveill...
Hong Yang, Steven H Lin, Annals of Surgical Oncology
Does Proton Therapy Offer Demonstrable Clinical Advantages for Treating Thoracic Tumors?☆
Zhongxing Liao, Saumil J Gandhi, Steven H Lin, ScienceDirect

Lectures

Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Nektar and Collaborators Present Late-Breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual MeetingNovember 7th, 2024
MD Anderson Research Highlights Special Edition: ESMO 2024September 10th, 2024
Is FLASH the Future of Radiation Therapy?September 30th, 2023
Join now to see all